ODAC supports the first triple set stimulation factor 1 receptor inhibitor pexidartinib for the treatment of symptomated tendoncytoma
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
TGCT, also known as pigmentation fluffy conjure skateitis (PVNS), or tendon cytoblastoma (GCT-TS), is a rare non-malignant tumor with localized aggressionIt can affect the joints, sacs and tendons covered by the sliding membrane, causing swelling, pain, stiffness, and decreased range of motion in the joints or limbstoday, daiichi Sankyocompany(http:// announcedthat the u.SFDA(http://oncologydrug(http://Advisory(http://Committee (http:// voted 12:3 to support the company's development of the set-by-the-block stimulant factor 1 receptor (CSF1R) inhibitor idpexib for the treatment of symptomatic tendonosis (TGC)if approved by the FDA, pexidartinib would be the first and only approved treatment for TGCTPexidartinib is an innovative oral CSF1R small molecule inhibitor The CSF1R-mediated signaling pathway is the main factor driving abnormal cell proliferation in the slip film Pexidartinib also inhibits the activity of c-kit and FLT3-ITD Pexidartinib has been awarded the FDA's ground-breaking therapeutic and orphan drug designations, and its new drug (http:// application (NDA) has also been qualified for priority review The FDA is expected to respond by August 3 The new drug's NDA is based on the results of a Phase 3 clinical trial (http:// called ENLIVEN The results showed that 39% of patients treated with pexidartinib received remission after 25 weeks of treatment, compared with 0% in the placebo group (p0.0001 ).
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
